Loading...
  • Infection
  • If there is a simultaneous co-infection with more than one pathogen (HIV and HepC for instance), what causes lower viremia levels during acute co-infection? (thebody.com)
  • To investigate the dynamics of parvovirus viraemia in asymptomatic blood donors, we studied the amounts of parvovirus DNA in pools of donor plasma, the prevalence of parvovirus antibodies among blood donors in relation to age, and the seasonal and year-to-year variation of the incidence of parvovirus infection in The Netherlands. (open.ac.uk)
  • The calculated clearance half-life for productively infected cells during resolution of the peak viremia of primary infection was on the order of 1 day, with slightly shorter clearance half-lives calculated during PMPA treatment. (pubmedcentralcanada.ca)
  • As lamivudine (3TC) monotherapy in HIV-HBV infection is associated with 3TC resistance in up to 90% of patients after 4 years,5 ongoing viremia despite HBV therapy raises concern for driving development of TDF and/or 3TC resistance. (natap.org)
  • clinical
  • The primary objective of this protocol is to provide access to tabelecleucel to patients with Epstein-Barr virus-positive post-transplant lymphoproliferative disorder (EBV+ PTLD), EBV+ primary immunodeficiency lymphoproliferative disease (PID LPD), EBV+ acquired immunodeficiency (AID) LPD, and EBV viremia for whom there are no other approved therapeutic options, and who are not eligible to enroll in clinical studies designed to support the development and registration of tabelecleucel. (clinicaltrials.gov)
  • Prompt identification of newly HIV-infected persons, particularly those who are most at risk of extended high viremia (EHV), allows important clinical and transmission prevention benefits. (nih.gov)
  • weeks
  • The researchers found that the addition of raltegravir to ART for 12 weeks did not demonstrably reduce low-level residual viremia in HIV-positive individuals receiving standard ART. (medindia.net)
  • Effect
  • In this randomized, controlled trial the researchers assessed whether the addition of raltegravir (a drug that inhibits HIV integrase) to standard ART had any effect on residual viremia. (medindia.net)
  • level
  • Viral blips during suppressive ART are not associated with increased CD8+ T cell activation, suggesting that transient low-level viremia is unlikely to worsen heightened level of CD8+ T cell activation. (natap.org)
  • Some studies show low-level viremia is more likely to happen on boosted PI-containing regimens. (thebodypro.com)